Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
PrEP, or pre-exposure prophylaxis, was first approved by the FDA in 2012 to prevent people exposed to HIV from becoming ...
PrEP is a medication that helps prevent HIV infection, and its inclusion would be a significant ... among hijra/transgender people is 18 times and among people who use drugs is 43 times of the overall ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
The rise in teenage pregnancies in South Africa underscores the challenges faced by adolescent mothers and the gaps in sexual and reproductive health services.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback